Lipella Pharmaceuticals (Lipella Pharmaceuticals) Additional Paid-In Capital : $14.08 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals Additional Paid-In Capital?

Lipella Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2023 ($11.86 Mil) to Dec. 2023 ($13.47 Mil) and increased from Dec. 2023 ($13.47 Mil) to Mar. 2024 ($14.08 Mil).

Lipella Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 ($4.53 Mil) to Dec. 2022 ($10.38 Mil) and increased from Dec. 2022 ($10.38 Mil) to Dec. 2023 ($13.47 Mil).

Lipella Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Lipella Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals Additional Paid-In Capital Chart

Lipella Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

1.70

4.53

10.38

13.47

Lipella Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial									10.59	11.44	11.86	13.47	14.08

Lipella Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Lipella Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208

Website

https://www.lipella.com

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.

Executives

Lori Birder	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman	director, 10 percent owner, officer: See Remarks	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston	officer: Chief Financial Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor	director, 10 percent owner, officer: Chief Medical Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208